Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry
- PMID: 7675990
Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry
Abstract
There is concern in developed countries about the increasing cost of health care. Developers of new psychopharmacologic agents are asked to demonstrate cost-effectiveness as well as safety and efficacy before widespread use is encouraged. Pharmacoeconomic studies are designed to evaluate the health outcomes and cost-effectiveness of new medical treatments relative to existing treatments. Retrospective and prospective research designs have been used in pharmacoeconomic studies. New approaches such as medical effectiveness studies and modeling studies based on clinical decision analysis are increasingly used to evaluate cost-effectiveness. This article introduces important concepts of pharmacoeconomic evaluation and discusses the methods and their strengths and weaknesses. Safety and efficacy studies and pharmacoeconomic studies provide useful and complementary evidence on how a new treatment affects clinical, health-related quality-of-life, and economic outcomes.
Similar articles
-
Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia.J Psychiatry Neurosci. 1997 Jul;22(4):256-66. J Psychiatry Neurosci. 1997. PMID: 9262048 Free PMC article. Review.
-
Re-engineering drug development: integrating pharmacoeconomic research into the drug development process.Psychopharmacol Bull. 1995;31(1):67-73. Psychopharmacol Bull. 1995. PMID: 7675991 Review.
-
The importance of considering non-monetary costs and benefits in selecting pharmacologic interventions in mental health.Psychopharmacol Bull. 1995;31(4):727-34. Psychopharmacol Bull. 1995. PMID: 8851646 Review.
-
Pharmacoeconomic concepts in antiplatelet therapy: understanding cost-effectiveness analyses using clopidogrel as an example.J Cardiovasc Pharmacol Ther. 2008 Jun;13(2):107-19. doi: 10.1177/1074248407313151. J Cardiovasc Pharmacol Ther. 2008. PMID: 18495905
-
[Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].Wien Med Wochenschr. 2006 Dec;156(23-24):612-8. doi: 10.1007/s10354-006-0357-7. Wien Med Wochenschr. 2006. PMID: 17211765 German.
Cited by
-
Fluoxetine. A pharmacoeconomic review of its use in depression.Pharmacoeconomics. 1998 May;13(5 Pt 1):543-61. doi: 10.2165/00019053-199813050-00007. Pharmacoeconomics. 1998. PMID: 10180753 Review.
-
Modelling the cost effectiveness of antidepressant treatment in primary care.Pharmacoeconomics. 1995 Dec;8(6):524-40. doi: 10.2165/00019053-199508060-00007. Pharmacoeconomics. 1995. PMID: 10160081
-
Quality of life rediscovered: implications for clinical outcome and health economics in schizophrenia.J Psychiatry Neurosci. 1997 Jul;22(4):229-30. J Psychiatry Neurosci. 1997. PMID: 9262043 Free PMC article. No abstract available.
-
Quality of life measurement during antipsychotic drug therapy of schizophrenia.J Psychiatry Neurosci. 1997 Jul;22(4):267-74. J Psychiatry Neurosci. 1997. PMID: 9262049 Free PMC article. Review.
-
Assessing health utilities in schizophrenia. A feasibility study.Pharmacoeconomics. 2000 Mar;17(3):273-86. doi: 10.2165/00019053-200017030-00005. Pharmacoeconomics. 2000. PMID: 10947302 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical